Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Taxol-oligoarginine conjugates overcome drug resistance in-vitro in human ovarian carcinoma.

Wender PA, Galliher WC, Bhat NM, Pillow TH, Bieber MM, Teng NN.

Gynecol Oncol. 2012 Jul;126(1):118-23. doi: 10.1016/j.ygyno.2012.03.049. Epub 2012 Apr 6.

2.

Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters.

Dubikovskaya EA, Thorne SH, Pillow TH, Contag CH, Wender PA.

Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12128-33. doi: 10.1073/pnas.0805374105. Epub 2008 Aug 19.

3.

Cell-penetrating, guanidinium-rich molecular transporters for overcoming efflux-mediated multidrug resistance.

Vargas JR, Stanzl EG, Teng NN, Wender PA.

Mol Pharm. 2014 Aug 4;11(8):2553-65. doi: 10.1021/mp500161z. Epub 2014 May 9. Review.

4.

Paclitaxel-2'-Ethylcarbonate prodrug can circumvent P-glycoprotein-mediated cellular efflux to increase drug cytotoxicity.

Tanino T, Nawa A, Kondo E, Kikkawa F, Daikoku T, Tsurumi T, Luo C, Nishiyama Y, Takayanagi Y, Nishimori K, Ichida S, Wada T, Miki Y, Iwaki M.

Pharm Res. 2007 Mar;24(3):555-65.

PMID:
17245652
5.

Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype.

Webster L, Linsenmeyer M, Millward M, Morton C, Bishop J, Woodcock D.

J Natl Cancer Inst. 1993 Oct 20;85(20):1685-90.

PMID:
8105099
6.
7.

Upregulation of phosphorylated cofilin 1 correlates with taxol resistance in human ovarian cancer in vitro and in vivo.

Li M, Yin J, Mao N, Pan L.

Oncol Rep. 2013 Jan;29(1):58-66. doi: 10.3892/or.2012.2078. Epub 2012 Oct 12.

PMID:
23064469
8.

Knock-down of P-glycoprotein reverses taxol resistance in ovarian cancer multicellular spheroids.

Xing H, Wang S, Weng D, Chen G, Yang X, Zhou J, Xu G, Lu Y, Ma D.

Oncol Rep. 2007 Jan;17(1):117-22.

PMID:
17143487
9.

Modulation of cisplatin sensitivity by taxol in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.

Yamamoto K, Kikuchi Y, Kudoh K, Nagata I.

J Cancer Res Clin Oncol. 2000 Mar;126(3):168-72. Erratum in: J Cancer Res Clin Oncol 2001 Feb;127(2):142.

PMID:
10741911
10.

A BTB/POZ gene, NAC-1, a tumor recurrence-associated gene, as a potential target for Taxol resistance in ovarian cancer.

Ishibashi M, Nakayama K, Yeasmin S, Katagiri A, Iida K, Nakayama N, Fukumoto M, Miyazaki K.

Clin Cancer Res. 2008 May 15;14(10):3149-55. doi: 10.1158/1078-0432.CCR-07-4358.

11.

Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP.

Dong X, Mattingly CA, Tseng MT, Cho MJ, Liu Y, Adams VR, Mumper RJ.

Cancer Res. 2009 May 1;69(9):3918-26. doi: 10.1158/0008-5472.CAN-08-2747. Epub 2009 Apr 21.

12.

Induction of a multifactorial resistance phenotype by high paclitaxel selective pressure in a human ovarian carcinoma cell line.

Violini S, D'Ascenzo S, Bagnoli M, Millimaggi D, Miotti S, Canevari S, Pavan A, Dolo V.

J Exp Clin Cancer Res. 2004 Mar;23(1):83-91.

PMID:
15149155
13.
14.

The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.

Horowitz NS, Hua J, Gibb RK, Mutch DG, Herzog TJ.

Gynecol Oncol. 2004 Jul;94(1):67-73.

PMID:
15262121
15.

Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance.

Vredenburg MR, Ojima I, Veith J, Pera P, Kee K, Cabral F, Sharma A, Kanter P, Greco WR, Bernacki RJ.

J Natl Cancer Inst. 2001 Aug 15;93(16):1234-45.

16.

Reversing drug resistance in the ovarian carcinoma cell line SKOV3/mdr1 in vitro by antisense oligodeoxynucleotides.

Pan L, Tong Y, Jin Y, Zhou S, Zhang Y, Yang X, Mao N.

Chin Med J (Engl). 2001 Sep;114(9):929-32.

PMID:
11780384
17.

[Reversal effect of PI-3K/Akt pathway inhibitor LY294002 on multidrug resistance of ovarian cancer cell line A2780/Taxol].

Shi XY, Cai XJ, Lei JX, Cao FJ, Pan DF, Chen P.

Ai Zheng. 2008 Apr;27(4):343-7. Chinese.

PMID:
18423117
18.

Emodin sensitizes paclitaxel-resistant human ovarian cancer cells to paclitaxel-induced apoptosis in vitro.

Li J, Liu P, Mao H, Wanga A, Zhang X.

Oncol Rep. 2009 Jun;21(6):1605-10.

PMID:
19424643
19.

MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells.

Li Z, Hu S, Wang J, Cai J, Xiao L, Yu L, Wang Z.

Gynecol Oncol. 2010 Oct;119(1):125-30. doi: 10.1016/j.ygyno.2010.06.004. Epub 2010 Jul 10.

PMID:
20624637
20.

Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro.

Jekunen AP, Christen RD, Shalinsky DR, Howell SB.

Br J Cancer. 1994 Feb;69(2):299-306.

Items per page

Supplemental Content

Write to the Help Desk